Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › NantHealth Submits GPS Cancer Test to FDA, Debuts AI Platform for Tumor ID

NantHealth Submits GPS Cancer Test to FDA, Debuts AI Platform for Tumor ID

Feb 12, 2018
|
Neil Versel
Premium

CHICAGO (GenomeWeb) – NantHealth, fresh off a tough 2017 that saw the company cut 300 jobs and face a series of lawsuits related to its 2016 initial public offering, is betting on new technology and assays to carry it into the future.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Aug
12
Featured Webinar

Demystifying COVID-19 Antibody Testing

Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. Germany Starts Going After Coronavirus Cases With Free Testing for Returning Travelers

    Premium

  2. Luminex Responds to FDA Warning Letter While Ramping SARS-CoV-2 Test Manufacturing

    Premium

  3. NHS Will Roll Out COVID-19 Tests From DnaNudge, Oxford Nanopore Across UK

  4. Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

    Premium

  5. Vela Diagnostics, Capstone Healthcare Get FDA Emergency Use Authorization for Coronavirus Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.